Skip to main content

Table 5 Adverse events reported in ≥ 20% of patients if grade 2 or if grades 3–4 occurring at any frequency

From: EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Adverse event, n (%) Arm A, 100 mg/m2 (n = 79) Arm B, 125 mg/m2 (n = 79)
All Grade 2 Grade 3 Grade 4 All Grade 2 Grade 3 Grade 4
Anaemia 67 (85) 26 (33) 2 (2.5) 66 (83.5) 29 (37)
Leucopaenia 47 (59) 20 (25) 7 (9) 58 (73) 23 (29) 15 (19) 1 (1)
Neutropaenia 46 (58) 18 (23) 14 (18) 1 (1) 55 (67) 13 (16) 25 (32) 3 (4)
Fatigue 60 (76) 25 (32) 9 (11) 60 (76) 36 (46) 4 (5)
Peripheral neuropathy 43 (54) 12 (15) 3 (4) 51 (64.5) 22 (28) 8 (10)
Nausea/vomiting 37 (47) 8 (10) 1 (1) 30 (38) 12 (15) 2 (2.5)
Alopecia 35 (44) 24 (30) / / 32 (40.5) 21 (27) / /
Myalgia/arthralgia 33 (42) 11 (14) 1 (1) 33 (42) 9 (11)
Dyspnoea 14 (18) 4 (5) 15 (19) 1 (1) 1 (1)
Fever 14 (18) 2 (2.5) 14 (18) 1 (1)
Hepatotoxicity 14 (18) 5 (6) 2 (2.5) 16 (20) 1 (1) 1 (1)
Infection 16 (20) 8 (10) 2 (2.5) 1 (1) 8 (10)° 3 (4)
Diarrhoea 11 (14) 3 (4) 4 (5) 15 (19)° 5 (6)
Renal toxicity 2 (2.5)° 1 (1) 4 (6) 1 (1)
Febrile neutropenia 1 (1) / 1 (1) 2 (2.5) / 2 (2.5)
  1. CTCAE Common Terminology Criteria for Adverse Events, / corresponding grade does not exist for this adverse event
  2. °Grade 5 (n = 1)